Extension of Study ZPV-200
The purpose of this study is to determine the safety, pharmacokinetics and efficacy of four doses of vaginally administered Proellex in premenopausal women with uterine fibroids confirmed by ultrasound.
Uterine Fibroids
DRUG: telepristone acetate 12 mg|DRUG: telepristone acetate 3 mg|DRUG: telepristone acetate 6 mg|DRUG: telepristone acetate 12 mg|DRUG: telepristone acetate 24 mg
Bleeding Scores, The primary efficacy endpoint will be bleeding assessed using the change in PBAC scores from the 4 weeks prior to Visit 2 to the 4 weeks prior to Visit 10, 3 or 4 months depending on treatment arm
The purpose of this study is to determine the safety, pharmacokinetics and efficacy of four doses of vaginally administered Proellex in premenopausal women with uterine fibroids confirmed by ultrasound.